ÂÜÀòÂÒÂ×

Scot Matkovich is an accomplished researcher with extensive experience in computational biology and cardiovascular medicine. As a Director at Eli Lilly and Company from August 2018 to July 2024, Scot contributed to preclinical drug discovery focused on cardiovascular diseases and diabetic complications, particularly in incretin biology. Prior to this role, Scot served as an Assistant Professor at Washington University in St. Louis, where leadership of an independent laboratory focused on cardiovascular noncoding RNA and research on microRNA roles in heart failure. In earlier positions at the University of Cincinnati and Columbia University Medical Center, Scot honed expertise in cardiac protein kinase C biology and studied phosphorylation effects on IP3R behavior. Scot holds a BA, BSc(Hons.), and PhD in biochemistry, molecular biology, physiology, French, German, and music from the University of Melbourne.